Vercise Neural Navigator with STIMVIEW XT allows clinicians to visualise lead placement and stimulation modelling of the brain anatomy of Parkinson’s disease or essential tremor patients. Credit: Boston Scientific Corporation.

The US Food and Drug Administration (FDA) has granted approval to Boston Scientific’s Vercise Neural Navigator with STIMVIEW XT, the next-generation image-guided programming software for deep brain stimulation (DBS) therapy.

STIMVIEW XT has been developed in collaboration with software-driven medical technology company Brainlab.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It allows clinicians to visualise real-time lead placement and stimulation modelling of brain anatomy for Parkinson’s disease or essential tremor patients.

An integrated visualisation software for DBS programming, STIMVIEW XT is used in combination with the Vercise Genus Deep Brain Stimulation portfolio.

It provides patient-specific 3D visualisation of brain anatomy for the personalisation of therapy.

The company stated that the Vercise Neural Navigator with STIMVIEW XT has been designed to minimise programming time, help localise lead placement and enable informed treatment.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Boston Scientific Neuromodulation senior vice-president Maulik Nanavaty said: “Every person’s experience living with Parkinson’s disease or essential tremor is unique, and their treatment should be as unique.

“Our technologies enable clinicians to precisely see, shape and steer DBS therapy to meet their patients’ individual needs.

“This latest advancement is a testament to how we’ll continue to deliver on meaningful innovations that support doctors.”

Using Boston Scientific visualisation software, clinicians in a recent study were able to adjust patient stimulation to an average of 20 minutes, reducing the programming time by 56%.

The company stated that the launch of the latest image-guided programming software in the US, which follows its launch in Europe, will provide broader access to clinicians treating Parkinson’s disease or essential tremor patients.

In January, Boston Scientific and GE Healthcare collaborated to provide an end-to-end interventional cardiac care portfolio in South-East Asia.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact